alexa Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Bioequivalence & Bioavailability

Author(s): Ward A, Clissold SP

Abstract Share this page

Abstract Pentoxifylline (oxpentifylline) is an orally active haemorheological agent for the treatment of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation. Pentoxifylline acts primarily by increasing red blood cell deformability, by reducing blood viscosity and by decreasing the potential for platelet aggregation and thrombus formation. Extensive open and placebo-controlled studies have shown that pentoxifylline 600 to 1200 mg/day for at least 6 weeks is associated with subjective and objective improvements in 60 to 100\% of patients with peripheral vascular disease. The most commonly assessed clinical parameter, walking distance, is usually improved by about 100\%, although much greater improvements have also been documented. Other parameters which have been clearly improved include lower limb rest pain, paraesthesia, muscle blood flow, cramps and leg ulcers. Pentoxifylline has produced consistently better results than placebo, and in those studies using comparative drugs, better results than nylidrin, adenosine and naftidrofuryl. In patients with cerebrovascular disorders, open studies with pentoxifylline, usually at a dosage of 600 to 1200 mg/day (300 to 600 mg/day in Japan), have shown marked overall clinical improvements in about 85\% of patients. Symptomatic improvements in rehabilitation psychometric tests, neuromotor and speech deficits and other subjective symptoms have accompanied increased cerebral blood flow, particularly to ischaemic areas. Pentoxifylline would appear to be useful in most types of cerebrovascular disease including transient ischaemic attacks, sequelae of cerebral thrombosis and haemorrhage, and chronic ischaemic disorders. In patients with chronic cerebrovascular disease pentoxifylline 600 to 1200 mg/day conferred significant clinical benefit compared with placebo and in isolated studies proved to be superior to drugs such as co-dergocrine mesylate, adenosine and pyrithioxine. Preliminary studies indicate that pentoxifylline may also prove useful in vaso-occlusive crises of sickle cell disease, some hearing disorders, disorders of eye circulation, high altitude sickness and asthenozoospermia. Pentoxifylline is usually well tolerated when administered as the conventional controlled release formulation, gastrointestinal symptoms (about 3\%) being the most common complaint, although these and other adverse effects have not occurred to a significantly greater extent than with placebo. Thus, pentoxifylline offers a well-tolerated and effective alternative to the treatment options available for patients with peripheral vascular disease.(ABSTRACT TRUNCATED AT 400 WORDS)
This article was published in Drugs and referenced in Journal of Bioequivalence & Bioavailability

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ensieh Shahvazian
    Resequencing of KLF14 gene in population based family study with type two diabetes
    PPT Version | PDF Version
  • Changchun Yang
    Feasibility study on DCA microspheres for deep profile control technology in high permeability of high temperature and high salt reservoirs
    PPT Version | PDF Version
  • Seema Narayan
    A comparative study of the link between real exchange rate of ASEAN countries and fossil fuel prices
    PDF Version
  • Navinchandra G. Ashar
    Comparative study of techno-economic evaluation of the production of liquid Sulphur Di Oxide
    PDF Version
  • Recep Çelik
    GIS based assessment effect of irrigation on groundwater level changes in agricultural areas: A case study on the Bismil plain in the Upper Tigris Basin
    PPT Version | PDF Version
  • Wondalem Misganaw Golie
    Adsorption equilibrium and kinetic study of removal of nitrate from drinking water supplies by chitosan composite
    PPT Version | PDF Version
  • Gunilla Lindqvist
    Chronic obstructive pulmonary disease: A study of the relationship between patients’ feeling of guilt due to their belief of the disease being self inflicted
    PDF Version
  • Rohit A
    Cardiovascular risk prediction using WHO/ISH chart in urban and rural subjects attending diabetes screening clinic: A pilot study
    PPT Version | PDF Version
  • Jahid Zeghiche
    Jahid-Zeghiche-Univesity-of-Al-Baha- Saudi-Arabia- Compressive- Strength-of-Concerete-filled-Thin- Steel-Stubs-Theoretical-and-Experimental-Study
    PPT Version | PDF Version
  • Won-SeokHeo
    Won-SeokHeo-Seoul-National-University-Republic-of-Korea-A-numerical-study-on-prediction-of-the-aerodynamic-performance-and-design-of-a-centrifugal-compressor
    PPT Version | PDF Version
  • Yi-Cheng Hu
    Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifentreated female breast cancer survivors in Taiwan between 1998 and 2008: A population-based study
    PPT Version | PDF Version
  • Carsten Worsoe
    The value of the “simulated study” as a tool to predict actual leachables in parenteral drug products
    PPT Version | PDF Version
  • Wei Gong
    Wei Gong-Huazhong-University-of-Science-and-Technology-China-Probabilistic-seismic-hazard-assessment-for-the-pseudo-negative-stiffness-control-of- a-steel-base-isolated-building-A-comparative-study-
    PPT Version | PDF Version
  • Abdullah Altin
    Abdullah-Altin-Van-Yuzuncu-Yıl-University-Turkey-A-comparative-study-on-optimization-of-machining-parameters-by-turning-nickel-based-super-alloys-according-to-taguchi-method
    PPT Version | PDF Version
  • Ganesh Raj Pant
    A serological study in response to people at occupational risk of rabies virus exposure in Nepal
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords